FGF23 and Cardiovascular Damage in Anemia With an Without Chronic Kidney Disease. — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

FGF23 and Cardiovascular Damage in Anemia With an Without Chronic Kidney Disease. — Stella

Home/Fibroblast Growth Factor 23/

View on ClinicalTrials.gov

Recruiting

Back to Fibroblast Growth Factor 23 trials

Trial locations(1 site)

Spain

Hospital Universitario Reina Sofia, Córdoba

Key details

Sponsor

Maimónides Biomedical Research Institute of Córdoba

Collaborators

Fondo de Investigacion Sanitaria

Enrollment target

~401 participants

Started

October 2021

Primary completion

July 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 85 Years

Last updated February 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.